FBLN5

Across TCGA pan-cancer cohorts, FBLN5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FBLN5 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FBLN5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FBLN5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where FBLN5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.687	0.400	<.001	65	view →
CCRCC	OS	Tertile	IV	0.198	0.830	.024	18	view →
LUAD	DFS	Median	All	0.951	0.635	.006	8	view →
GBM	OS	Quartile	All	0.690	0.965	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FBLN5–PDAC (OS)

Open the PDAC breakdown →